FDA Lets Vera Analyze Atacicept Phase 3 Data a Year Early as Accelerated Approval Decision Nears
Vera Therapeutics reached an agreement with the FDA to speed up analysis of its confirmatory Phase 3 study for atacicept in IgA nephropathy. A decision on accelerated approval is expected by July 7.
StatVera Therapeutics reached an agreement with the FDA to accelerate analysis of its confirmatory Phase 3 study for atacicept in IgA nephropathy. The drug is already under review for accelerated approval, with a decision expected by July 7. The new agreement allows Vera to analyze the Phase 3 study in the third quarter rather than waiting for an additional year of data.
Convergent Therapeutics demonstrated that its experimental therapy could extend the lives of prostate cancer patients even after chemotherapy and Novartis' radiation therapy Pluvicto stopped working. Abivax said its experimental treatment for ulcerative colitis showed significant efficacy in a maintenance trial. The data were announced on June 1, 2026.
The article was published on June 2, 2026 by Elaine Chen, National Biotech Reporter at STAT. Chen co-writes The Readout newsletter and co-hosts STAT’s weekly biotech podcast The Readout Loud. com.
Transparency
Reported by a single outlet. This score reflects source tier and factual specificity — corroboration is limited with one source.
Story details
Related Stories
France 24WHO Reports 330 Confirmed Ebola Cases and 49 Deaths as Suspected Tally Falls to 116
The World Health Organization on Tuesday lowered its count of suspected Ebola cases from 906 to 116 after testing ruled out other illnesses. Confirmed cases stand at 330 across the Democratic Republic of Congo and Uganda.
Ebola Response Expands in Eastern DRC Despite Equipment and Tracing Challenges
Dr. Abdou Sebushishe of the International Medical Corps told CNN that efforts to contain the outbreak are growing while protective gear, contact tracing, and public trust remain limited.
The Hill**Judge Temporarily Blocks NSF Supercomputer Transfer from NCAR**
A federal judge issued a preliminary injunction blocking the transfer of a supercomputer used for climate and weather research. The ruling preserves operations at the National Center for Atmospheric Research in Boulder pending further review.